

RNS Number : 4791L

Ovoca Bio PLC

05 June 2025

Ovoca Bio PLC
5 June 2025

Ovoca Bio plc
("Ovoca" or the "Company")

Delisting from Euronext Growth Exchange

Further to the Company's press release of 7 May 2025, Ovoca confirms that the admission of Ovoca Ordinary Shares to trading on Euronext Growth was cancelled with effect from 7.00 am today, 5 June 2025 (the "Cancellation"). The Company will remain listed on the AIM Market of the London Stock Exchange, although presently share trading is suspended and has been since May 7, 2025.

As previously stated, the Cancellation was agreed to by the Board of the Company to consolidate trading of the Company's ordinary shares to the AIM Market, where the majority of the trading liquidity in the Company's ordinary shares is located. The Cancellation will also remove certain costs, complexities and duplication that comes from administering two listing regimes and will have no impact on Ovoca's Ordinary Shares which will continue to be admitted to AIM.

End

For further information:

Ovoca Bio plc

Timothy McCutcheon (Chief Executive Officer)
Tel +353 1 661 9819
info@ovocabio.com

Beaumont Cornish Limited (Nominated Adviser and Broker)

James Biddle/ Roland Cornish
Tel: +44 (0) 207 628 3396

Davy (Euronext Growth Listing Sponsor)

Ivan Murphy / Daragh O'Reilly
Tel: +353 1 679 6363

Beaumont Cornish Limited ("Beaumont Cornish") is the Company's Nominated Adviser and is authorised and regulated by the FCA. Beaumont Cornish's responsibilities as the Company's Nominated Adviser, including a responsibility to advise and guide the Company on its responsibilities under the AIM Rules for Companies and AIM Rules for Nominated Advisers, are owed solely to the London Stock Exchange. Beaumont Cornish is not acting for and will not be responsible to any other persons for providing protections afforded to customers of Beaumont Cornish nor for advising them in relation to the proposed arrangements described in this announcement or any matter referred to in it.

Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@lse.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCSSEFILEISEDM